Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation

Archive ouverte

Triaille, Clément | Rao, Neha Mohan | Rice, Gillian | Seabra, Luis | Sutherland, Fraser | Bondet, Vincent | Duffy, Darragh | Gennery, Andrew | Fournier, Benjamin | Bader-Meunier, Brigitte | Troedson, Christopher | Cleary, Gavin | Buso, Helena | Dalby-Payne, Jacqueline | Ranade, Prajakta | Jansen, Katrien | de Somer, Lien | Frémond, Marie-Louise | Chavan, Pallavi Pimpale | Wong, Melanie | Dale, Russell | Wouters, Carine | Quartier, Pierre | Khubchandani, Raju | Crow, Yanick

Edité par CCSD ; Springer Verlag -

International audience. Hereditary C1q deficiency (C1QDef) is a rare monogenic disorder leading to defective complement pathway activation and systemic lupus erythematosus (SLE)-like manifestations. The link between impairment of the complement cascade and autoimmunity remains incompletely understood. Here, we assessed type 1 interferon pathway activation in patients with C1QDef. Twelve patients with genetically confirmed C1QDef were recruited through an international collaboration. Clinical, biological and radiological data were collected retrospectively. The expression of a standardized panel of interferon stimulated genes (ISGs) in peripheral blood was measured, and the level of interferon alpha (IFNα) protein in cerebrospinal fluid (CSF) determined using SIMOA technology. Central nervous system (encompassing basal ganglia calcification, encephalitis, vasculitis, chronic pachymeningitis), mucocutaneous and renal involvement were present, respectively, in 10, 11 and 2 of 12 patients, and severe infections recorded in 2/12 patients. Elevated ISG expression was observed in all patients tested ( n = 10/10), and serum and CSF IFNα elevated in 2/2 patients. Three patients were treated with Janus-kinase inhibitors (JAKi), with variable outcome; one displaying an apparently favourable response in respect of cutaneous and neurological features, and two others experiencing persistent disease despite JAKi therapy. To our knowledge, we report the largest original series of genetically confirmed C1QDef yet described. Additionally, we present a review of all previously described genetically confirmed cases of C1QDef. Overall, individuals with C1QDef demonstrate many characteristics of recognized monogenic interferonopathies: particularly, cutaneous involvement (malar rash, acral vasculitic/papular rash, chilblains), SLE-like disease, basal ganglia calcification, increased expression of ISGs in peripheral blood, and elevated levels of CSF IFNα.

Suggestions

Du même auteur

Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients

Archive ouverte | Frémond, Marie-Louise | CCSD

International audience. Background: Gain-of-function mutations in STING1 underlie a type I interferonopathy termed SAVI (STING-associated vasculopathy with onset in infancy). This severe disease is variably characte...

Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling

Archive ouverte | Melki, Isabelle | CCSD

International audience

Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A

Archive ouverte | Lepelley, Alice | CCSD

International audience. Mitochondrial DNA (mtDNA) has been suggested to drive immune system activation, but the induction of interferon signaling by mtDNA has not been demonstrated in a Mendelian mitochondrial disea...

Chargement des enrichissements...